Question 1

What is Vaderis Therapeutics?

Accepted Answer

Vaderis Therapeutics is a Entity.

Question 2

How often does Vaderis Therapeutics appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 8 articles.

Question 3

When was Vaderis Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on Aug 11, 2026.

Question 4

When was Vaderis Therapeutics last mentioned in news?

Accepted Answer

Last active on Aug 11, 2026.

Question 5

What is Vaderis Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Vaderis Therapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Vaderis Therapeutics?

Accepted Answer

Vaderis $152M Series B and Phase 3 HEROIC (Aug 11, 2026, 8 articles).

Question 8

How did the "Vaderis $152M Series B and Phase 3 HEROIC" event impact Vaderis Therapeutics?

Accepted Answer

Vaderis closed a $152M Series B and initiated its Phase 3 HEROIC study, marking a pivotal transition. The funding extends its runway through potential U.S. approval of engasertib, enhancing its prospects as a first-in-class HHT therapy.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.